Silent suppression for Antisense

By Dylan Bushell-Embling
Wednesday, 15 October, 2008

Preclinical trials of Antisense Therapeutics’ [ASX: ANP] ATL1101 candidate have been shown to suppress human prostate tumour growth in animal models.

ATL1101 suppressed the growth of human tumours in mice that had been implanted with human prostate cancer sells.

The treatment slowed down the cancerous cells' transition to the most dangerous form of prostate cancer, castration-resistant prostate cancer [CRPC].

The study was conducted with the assistance of Martin Gleave, the director of the Prostate Centre at Vancouver General Hospital.

This is the first known demonstration of the efficacy of RNA-silencing IGF-I receptor drugs in prostate cancer models.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd